View of Intravenous Tocilizumab versus Standard of Care in the Treatment of Severe and Critical COVID-19-related Pneumonia: A Single Center, Double-blind, Placebo Controlled, Phase 3 Trial

Return to Article Details Intravenous Tocilizumab versus Standard of Care in the Treatment of Severe and Critical COVID-19-related Pneumonia: A Single Center, Double-blind, Placebo Controlled, Phase 3 Trial Download Download PDF